# Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors

> **NCT03348514** · PHASE1 · COMPLETED · sponsor: **CicloMed LLC** · enrollment: 19 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** CPX-POM - 30 mg/m^2
- **DRUG:** CPX-POM - 60 mg/m^2
- **DRUG:** CPX-POM - 120 mg/m^2
- **DRUG:** CPX-POM - 240 mg/m^2
- **DRUG:** CPX-POM - 360 mg/m^2
- **DRUG:** CPX-POM - 600 mg/m^2
- **DRUG:** CPX-POM - 900 mg/m^2
- **DRUG:** CPX-POM - 1200 mg/m^2

## Key facts

- **NCT ID:** NCT03348514
- **Lead sponsor:** CicloMed LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-15
- **Primary completion:** 2020-05-31
- **Final completion:** 2020-05-31
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2021-12-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03348514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03348514, "Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03348514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*